Adjuvant Therapy of Breast Cancer

References

• Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials.Lancet 1998, 352, 930–942. [CSA]
   PubMed Web of Science ®Google Scholar
• Eifel, P.; Axelson, J A.; Costa, J.; , et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000.J. Natl. Cancer Inst. 2001, 93, 979–989. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goldhirsch, A.; Wood, W C.; Gelber, R D.; , et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.J. Clin. Oncol. 2003, 21, 3357–3365. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mamounas, E P.; Bryant, J.; Lembersky, B C.; , et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.Proc. Am. Soc. Clin. Oncol. 2003, 22, 12. [CSA]
   Google Scholar
• Henderson, I C.; Berry, D A.; Demetri, G D.; , et al. Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J. Clin. Oncol. 2003, 21, 976–983. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Buzdar, A U.; Singletary, S E.; Valero, V.; , et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.Clin. Cancer Res. 2002, 8, 1073–1079. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Martin, M.; Lluch, A.; Seguí, A.; , et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study.Proc. Am. Soc. Clin. Oncol. 2004, 22 (14S), 620. [CSA]
   Google Scholar
• Skipper, H E. Laboratory models: some historical perspectives.Cancer Treat. Rep. 1986, 70, 3–7. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Norton, L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy.Oncologist 2001, 3 (Suppl.), 30–35. [CSA]
   Google Scholar
• Citron, M L.; Berry, D A.; Cirrincione, C.; , et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.J. Clin. Oncol. 2003, 21, 1431–1439. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Slamon, D J.; Godolphin, W.; Jones, L A.; , et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science 1989, 244, 707–712. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vogel, C L.; Cobleigh, M A.; Tripathy, D.; , et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J. Clin. Oncol. 2002, 20, 719–726. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pietras, R J.; Fendly, B M.; Chazin, V R.; , et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.Oncogene 1994, 9, 1829–1838. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Slamon, D J.; Leyland-Jones, B.; Shak, S.; , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N. Engl. J. Med. 2001, 344, 783–792. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Geyer, C E.; Bryant, J.; Romond, E.; , et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N + ), Her-2 overexpressing breast cancer (HER-2 + BC).Breast Cancer Res. Treat. 2004, 82 (Suppl. 1), S13. [CSA]
   Google Scholar
• Hortobagyi, G N.; Kau, S W.; Buzdar, A.; , et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?. Proc. Am. Soc. Clin. Oncol. 2004, 23, [CSA]
   Google Scholar
• Fisher, B.; Dignam, J.; Bryant, J.; , et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.J. Natl. Cancer Inst. 1996, 88, 1529–1542. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bryant, J.; Fisher, B.; Dignam, J. Duration of adjuvant tamoxifen therapy.J. Natl. Cancer Inst. Monographs 2001; 30: 56–61. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Goss, P.; Grynpas, M.; Qi, S.; Hu, H. The effects of exemestane on bone and lipids in the ovariectemized rat.Breast Cancer Res. Treat. 2001, 69, 224. [CSA]
   Web of Science ®Google Scholar
• Goss, P E.; Strasser, K. Aromatase inhibitors in the treatment and prevention of breast cancer.J. Clin. Oncol. 2001, 19, 881–894. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Group AT. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal women.Breast Cancer Res. Treat. 2001, 69, 210. [CSA]
   Web of Science ®Google Scholar
• Buzdar, A.; Jonat, W.; Howell, A.; , et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.J. Clin. Oncol. 1996, 14, 2000–2011. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Buzdar, A.; Douma, J.; Davidson, N.; , et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.J. Clin. Oncol. 2001, 19, 3357–3366. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kaufmann, M.; Bajetta, E.; Dirix, L Y.; , et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.J. Clin. Oncol. 2000, 18, 1399–1411. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mouridsen, H.; Gershanovich, M.; Sun, Y.; , et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.J. Clin. Oncol. 2001, 19, 2596–2606. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nabholtz, J M.; Buzdar, A.; Pollak, M.; , et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.J. Clin. Oncol. 2000, 18, 3758–3767. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bonneterre, J.; Thurlimann, B.; Robertson, J F.; , et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.J. Clin. Oncol. 2000, 18, 3748–3757. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.Lancet 2002, 359, 2131–2139. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Group TAT. The ATAC (arimidex, tamoxifen, alone or in combination) trial in postmenopausal women with early breast cancer—updated efficacy results based on a median follow-up of 47 months.Breast Cancer Res. Treat. 2002, 76, 12. [CSA]
   Google Scholar
• Winer, E P.; Hudis, C.; Burstein, H J.; , et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.J. Clin. Oncol. 2003, 21, 2597–2599. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Boccardo, F.; Rubagotti, A.; Amoroso, D.; , et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.J. Clin. Oncol. 2001, 19, 4209–4215. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Boccardo, F.; Rubagotti, A.; Amoroso, D.; , et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment.Breast Cancer Res. Treat. 2003, 82 (Suppl. 1), S6 Ref. Type: Abstract. [CSA]
   Google Scholar
• Jakesz, R.; Kaufmann, M.; Gnant, M.; , et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrazole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in teh ABCSG Trial 8 and the ARNO 95 Trial.Breast Cancer Res. Treat. 2004, 88 (Suppl. 1), S7. [CSA]
   Google Scholar
• Coombes, R C.; Hall, E.; Gibson, L J.; , et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.N. Engl. J. Med. 2004, 350, 1081–1092. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goss, P E.; Ingle, J N.; Martino, S.; , et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.N. Engl. J. Med. 2003, 349, 1793–1802. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goss, P.; Ingle, J N.; Martino, S.; , et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer.Proc. Am. Soc. Clin. Oncol. 2004, 22 (14S). [CSA]
   PubMedGoogle Scholar
• Beatson, G T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases.Lancet 1896, ii, 104–107. [CSA]
   Google Scholar
• Nicholson, R I.; Walker, K J.; Walker, R F.; , et al. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.Horm. Res. 1989, 32 (Suppl. 1), 198–201. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Martin, M.; Pienkowski, T.; Mackey, J.; , et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up.San Antonio Breast Cancer Symp. 2003; 82: 43. [CSA]
   Google Scholar
• Roche, H.; Mihura, J.; de Lafontan, B.; , et al. Castration and tamoxifen vs chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients: a randomized trial with a 7 years follow-up.Proc. Am. Soc. Clin. Oncol. 1996, 15, 134 Ref. Type: Abstract. [CSA]
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.J. Clin. Oncol. 2001, 19, 602–611. [CSA]
   PubMed Web of Science ®Google Scholar
• Arriagada, R.; Le, G M.; Spielmann, M.; , et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.Proc. Am. Soc. Clin. Oncol. 2003, 22, 14. [CSA]
   Google Scholar
• Davidson, N.; O'Neill, A.; Vukov, A.; , et al. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101).Proc. Am. Soc. Clin. Oncol. 2003, 22, 15. [CSA]
   PubMedGoogle Scholar
• Robert, N J.; Wang, M.; Cella, D.; , et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer? 3 cm.Proc. Am. Soc. Clin. Oncol. 2003, 22, 16 Ref. Type: Abstract. [CSA]
   Google Scholar